Background: Experimental findings using animal models of Parkinson disease (PD) suggest that noradrenaline might protect dopamine neurons from damage.
I
DIOPATHIC PARKINSON DISEASE (PD) is characterized by heterogeneous degeneration of brain dopamine neurons. 1 The cause of PD is unknown, and the reason why dopamine neurons in some brain areas are much more vulnerable to damage than those in others is unknown.
Neuropathological observations in PD of the loss of noradrenergic neurons originating in the locus coeruleus area 2 suggest that noradrenaline therapy might be helpful in symptomatic treatment of some aspects of PD. 3 Moreover, animal findings suggest that the loss of brain noradrenergic neurons in PD might exacerbate dopamine neuron damage and that noradrenaline could actually be neuroprotective. 4 The possible involvement of noradrenaline is especially interesting given findings of brain microglial activation in PD [5] [6] [7] [8] and the emerging role for noradrenaline as an endogenous anti-inflammatory agent. 9, 10 If the experimental animal data are relevant to the human, one might expect that brain regions having high levels of noradrenaline could be more protected against dopamine loss in PD. To address this possibility, we compared the extent of dopamine loss in different regions in autopsied brains of patients with PD with levels of noradrenaline found in healthy brain. Of 20 areas examined, an area of focus was the dopamine-rich nucleus accumbens (NACS), a striatal subdivision that contains a noradrenaline-poor rostral portion and a caudomedial subdivision that is strikingly enriched in noradrenaline.
11

METHODS
Autopsied brains were obtained (February 1982 to December 1990) from patients with PD (n = 10) and from healthy control subjects (n=11). The control subjects and the patients with PD did not differ significantly in their [5.9] hours, respectively; P=.14) (2-tailed t tests). Half of the brain was used for neuropathological examination, whereas the other half was frozen for neurochemical analyses. Clinical, drug history, and brain neuropathological findings for the patients with PD are summarized in Table 1 . All patients had received the clinical diagnosis of PD except for patient 8, who had been observed only briefly by a neurologist a few days before death and was considered at that time to have a neurological illness characterized by tremor. Postmortem brain neurochemical analyses of this patient showed the pattern of striatal dopamine loss that is characteristic of PD, and brain neuropathological analyses of this patient and all other patients with the clinical diagnosis of PD disclosed the characteristic histopathological signs of substantia nigra cell loss and the presence of Lewy bodies. All patients except for patient 8 had received dopamine substitution medication. No detailed information on the neuropsychological or mental function of the patients was available. Control subjects had died without evidence of neurological or psychiatric disease and showed no brain abnormality on neuropathological examination. The causes of death for the control subjects were myocardial infarction (n=3), cardiac failure (n=2), cancer (n=2), pulmonary embolism (n=2), diffuse interstitial pulmonary disease (n=1), and unknown (n=1).
Dissection of the brains and subdivisions of the striatum, including the NACS, followed procedures that have been published elsewhere. 11 Levels of dopamine and noradrenaline were measured by high-performance liquid chromatographyelectrochemical detection. 12 The primary outcome measure was correlation (Pearson product-moment correlation) among the brain areas examined between percentage dopamine loss in PD vs noradrenaline levels in healthy brain. Two-tailed t tests with Bonferroni correction for multiple comparisons were performed to examine differences between the control and PD groups.
Some neurochemical data have been previously published. These include caudate and putamen dopamine levels in 10 control subjects and in 8 patients with PD 13 ; hypothalamus dopamine and noradrenaline levels in 8 control subjects and in 9 patients with PD 14 ; and NACS dopamine and noradrenaline levels in 11 control subjects. 11 No significant correlation was observed between age or postmortem interval of the subjects and tissue levels of the monoamines in the control or PD group. Table 2 gives the control and patient levels of dopamine and noradrenaline in 1 cerebral and 19 subcortical cortical brain areas. Analysis in the cerebral cortex was limited to the cortical region, Brodmann area 25 (parolfactory cortex), which in the human contains a quantifiable amount of dopamine.
RESULTS
DOPAMINE AND NORADRENALINE LOSS
As expected, dopamine was decreased in all examined brain regions, but the magnitude of the reduction in the different brain areas was variable. Of the regions examined, the caudal portion of the putamen was the most affected (−97%) in PD, and the preoptic area of the hypothalamus was the least affected (−9%) ( Table 2 ). Concentrations of noradrenaline were generally more modestly decreased (Յ57% maximum reduction). No significant correlation (r =−0.17, PϾ.05) was observed between the extent of dopamine and noradrenaline loss in the 20 examined brain regions.
DOPAMINE LOSS VS NORADRENALINE CONCENTRATION
In the PD group, brain areas that in healthy subjects have high (Ͼ1 ng/mg) noradrenaline concentrations (the caudomedial NACS and rostral portions of the hypothalamus) showed less severe dopamine loss (−9% to −54%) compared with brain areas with low levels (Ͻ0.4 ng/mg) of the neurotransmitter (−61% to −97%) ( Table 2 ). This is best exemplified by the NACS and the striatal nuclei. In the NACS, the noradrenaline-rich caudomedial portion was spared (relative to the other NACS subdivisions) from severe dopamine depletion (Figure, A) , and in the noradrenaline-poor striatum, the dopamine loss was severe in the caudate and in the putamen. A correlational analysis using values from the 20 examined brain areas confirmed that the extent of the mean dopamine loss in the different brain regions was significantly inversely correlated with the levels of noradrenaline in healthy control subjects (r = 0.83, PϽ.001; Figure, B ) and in subjects with PD (r=0.82, PϽ.001). However, within the striatum (caudate and putamen), noradrenaline concentrations were low and were similar in the subdivisions that are most (caudal putamen, −97% dopamine loss) and least (caudal caudate, −61% dopamine loss) affected in PD (Table 2) .
COMMENT
Notwithstanding the many uncertainties inherent in human postmortem brain studies (eg, possible medication effects), we found that regions rich in noradrenaline had smaller dopamine losses than those in noradrenalinepoor areas in PD. This is best illustrated in the dopaminerich NACS, which has a noradrenaline-poor rostral portion and a caudal subdivision that is strikingly rich in .42 −28
*Data are given as mean (SD) (in nanograms per milligram of wet tissue) and represent 5 to 9 subjects for hypothalamic subdivisions and 6 to 11 subjects for all other brain regions. Caudate and putamen dopamine levels in 10 control subjects and in 8 patients with PD were previously published. 13 Data for the hypothalamus were published 14 and are reproduced with permission from Elsevier Science Publishers. Data for the nucleus accumbens of the control subjects have been published 11 and are reproduced with permission from the International Society for Neurochemistry. †PϽ.001, PD vs control (2-tailed t tests with Bonferroni adjustment). noradrenaline 11 and was particularly spared from dopamine loss in PD. This notion receives further support from the observation that dopamine loss is marked in the striatum (caudate and putamen), which contains low levels of noradrenaline. However, it is unlikely that a lack of noradrenaline could be the primary factor responsible for the dopamine neuron death. This is shown by our additional finding that levels of noradrenaline within the different subdivisions of the caudate and putamen were similar, although dopamine was much more markedly decreased in the subdivided putamen. This points to the subregionally selective effect of the still unknown primary factor (or factors) responsible for the nigrostriatal neurodegenerative process in PD.
In studies using animal models of PD caused by dopaminergic neurotoxins (eg, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 6-hydroxydopamine), striatal dopamine loss is more severe following lesions of the locus coeruleus noradrenergic pathway. [15] [16] [17] [18] Conversely, pharmacological enhancement of noradrenergic activity by an ␣ 2 -adrenergic antagonist, 19 by a noradrenaline transporter inhibitor, 20 or by genetic deletion of the noradrenaline transporter 20 was neuroprotective. This suggests the possibility that noradrenaline might have a neuroprotective role in PD. 4 The mechanism of neuroprotective action of noradrenaline in experimental studies is still debated 4 but could involve the neurotrophic function of the noradrenergic brain innervation 21 or, especially, the amine antiinflammatory potential. 9, 10 The loss of dopamine neurons in PD is accompanied by the appearance of activated microglial cells in brain [5] [6] [7] [8] that would be expected to have the capacity to produce cytokines (eg, tumor necrosis factor ␣ and interleukin 1␤) and other proinflammatory molecules, thereby aggravating neuronal cell death. 22 In this context, experimental studies 9, 10 have revealed that noradrenaline can inhibit several aspects of the microglial reaction (including the expression of tumor necrosis factor ␣ and interleukin 1␤) and thus has the potential of an endogenous anti-inflammatory agent in the brain. Future studies should establish whether the regional extent of microglial activation in PD is inversely related to the brain regional noradrenergic innervation.
CONCLUSIONS
Our postmortem brain findings (although only correlational) provide support to the notion (based on animal data) that clinical therapeutic approaches designed to enhance brain noradrenergic activity (eg, by ␣ 2 -adrenergic antagonists and noradrenaline transporter inhibitors) should be considered as possible neuroprotective strategies in PD. This potential neuroprotective action of noradrenaline should also be kept in mind when treating patients having PD with noradrenergic compounds (eg, noradrenaline transporter inhibitors for depression 23, 24 ) for symptomatic purposes. Table 2 . The solid circles indicate subdivisions of the striatum (caudate, putamen, and NACS). Noradrenaline levels in the NACS of the control subjects have been published 11 and are reproduced with permission from the International Society for Neurochemistry. 
